LMA Supraglottic Leak Pressure & Cuff Optimization 2026
LMA Cuff Optimization & Supraglottic Leak Pressure 2026
Achieving optimal oropharyngeal leak pressure while limiting mucosal injury is the central engineering challenge in supraglottic airway device design. This dataset spans patents and clinical literature from 1993 to 2025 across cuff P-V engineering, device architecture, monitoring, and non-inflatable alternatives.
Engineering the LMA Cuff: Seal Pressure, Mucosal Safety, and Device Architecture
Laryngeal mask airway cuff optimization sits at the intersection of medical device design, materials science, and anesthesiology practice. The core engineering challenge is balancing supraglottic seal pressure — sufficient to prevent gas leak during positive pressure ventilation — against mucosal pressure that causes postoperative sore throat, hoarseness, and dysphagia. This dataset captures innovation signals spanning four principal technical sub-domains from 1993 to 2025.
Clinical literature within this dataset consistently identifies 25 cmH₂O as the emerging operative standard for maximum intracuff pressure. A 2014 prospective randomized study demonstrated that limiting LMA Supreme cuff pressure to 25 cmH₂O reduced postoperative sore throat and dysphagia versus inflation to the manufacturer maximum of 60 cmH₂O, without compromising seal adequacy in standard surgical cases.
Second- and third-generation supraglottic airway devices — including LMA ProSeal, LMA Supreme, i-gel, Baska Mask, AuraGain, and LMA Protector — are displacing endotracheal intubation across an expanding range of surgical indications. Mean oropharyngeal leak pressures of 24–35 cmH₂O are consistently reported across second-generation SGAs at standard cuff inflation pressures in clinical trials within this dataset.
Patent activity in this dataset is moderately concentrated: Airway Medix S.A. holds the most coherent active IP cluster on cuff pressure-volume curve engineering, with 3 active US patents filed 2019–2020. Indian Ocean Medical Inc. and Hospitech Respiration Ltd. represent additional active monitoring-focused positions in retrieved records. Chinese manufacturers Zhejiang Jenston and Henan Tuoren hold active US and EP grants respectively for device architecture innovations.
Filing Trends and Clinical Performance Benchmarks Across the LMA Cuff Dataset
Patent filings in this dataset span from foundational inactive architecture patents (1993–2010) through an active engineering innovation period (2017–2022) to emerging integrated visualization and monitoring filings (2024–2025). Clinical literature benchmarks consistently establish oropharyngeal leak pressure and mucosal pressure as the dual performance axes for SGA evaluation.
Patent Filing Activity by Innovation Period — LMA Cuff Optimization (Dataset Snapshot)
In this dataset, the 2017–2022 engineering innovation period accounts for the highest concentration of active patent filings, led by Airway Medix P-V curve and Zhejiang Jenston endoscopic LMA portfolios.
↗ Click bars to exploreReported Mean Oropharyngeal Leak Pressure by SGA Device Type (Clinical Literature in This Dataset)
Across clinical studies in this dataset, second-generation SGAs report mean OLPs ranging from 24 cmH₂O (i-gel, LMA Supreme) to 35 cmH₂O (LMA ProSeal, Baska Mask), with the Baska Mask demonstrating statistically higher seal pressure than ProSeal in a 2023 RCT.
↗ Click bars to exploreKey Surgical and Procedural Applications of LMA Cuff Technology Across Clinical Settings
LMA cuff optimization technology is evaluated across multiple clinical settings in this dataset, from routine elective surgery to specialized laparoscopic, endoscopic, ENT, and intensive care applications, each imposing distinct seal pressure and device geometry requirements.
General and Elective Surgery
A 2021 network meta-analysis synthesizing 108 RCTs (n=10,645) compared 17 SGA types on OLP, first-attempt failure, and sore throat rate — the most comprehensive comparative dataset in this collection. OLPs of 24–35 cmH₂O are consistently reported across second-generation SGAs at standard inflation pressures. A 2014 prospective randomized study confirmed that limiting LMA Supreme cuff pressure to 25 cmH₂O reduced postoperative pharyngolaryngeal adverse events versus 60 cmH₂O inflation.
Comparative EffectivenessLaparoscopic Cholecystectomy and Gynaecology
Pneumoperitoneum and Trendelenburg positioning increase airway pressure demands, requiring SGAs to maintain seal above 20–25 cmH₂O. A 140-patient study (2012) documented LMA Supreme OLP adequacy during gynaecological laparoscopy under pneumoperitoneum conditions. A 2017 study comparing AuraGain and ProSeal in laparoscopic cholecystectomy found comparable OLP with lower calculated pharyngeal mucosal pressure in the AuraGain group.
Laparoscopic SurgeryEndoscopic and GI Procedures
Intracuff pressure changes caused by endoscope passage are identified as a primary safety concern in GI procedures. A 200-patient pediatric RCT (2020) validated the LMA Gastro Airway’s dedicated internal-channel design that isolates cuff integrity during endoscope passage. The Zhejiang Jenston 2022 US active patent describes an endoscopic LMA with parallel ventilation, endoscope, and inflation channels supporting esophagoscopes up to 17 mm diameter.
Endoscopic ProceduresHead, Neck, and Sinus Surgery
Flexible LMAs are used in functional endoscopic sinus surgery (FESS) where reinforced tube geometry is required. A large 5-year retrospective study covering 6,661 patients (2021) documented safety and efficacy of flexible LMAs in FESS with low complication rates — the largest single-procedure LMA safety dataset in this collection. ProSeal LMA was also validated during bronchoscope-guided percutaneous tracheostomy in 60 ICU patients, achieving peak inspiratory pressures of 25 cmH₂O with minimal tidal volume loss.
ENT and ICUKey Patent Assignees in LMA Cuff Optimization — Dataset Snapshot
In this dataset, Airway Medix S.A. holds the most concentrated active IP cluster with 3 active US patents on cuff P-V curve engineering filed 2019–2020, while Indian Ocean Medical Inc. spans the broadest jurisdictional footprint with filings across US, AU, and CA from 1993–2018 in retrieved records.
Top Assignees by Patent Filing Count — LMA Cuff Optimization (Dataset Snapshot)
↗ Click bars to exploreAirway Medix S.A.
Airway Medix S.A. holds 3 active US patents filed 2019–2020 defining novel pressure-volume curve geometries for LMA cuffs, including a local pressure maximum between 15–120 cmH₂O at medium volumes and a sustained medium-pressure plateau at high volumes. A PCT application filed under inventor Oron Zachar (2019, WO) extends geographic coverage with substantially identical P-V curve claims. These patents establish that the medium-pressure-range rate of change must be less than 0.5× the low-pressure-range rate, creating a self-limiting cuff inflation architecture — the most concentrated active IP position on cuff P-V optimization in this dataset.
IsraelIndian Ocean Medical Inc.
Indian Ocean Medical Inc. holds active US patents (2013, 2018) covering monitoring of leaks, blockages, and malpositioning of inflatable-cuff airway devices, with direct transferability to LMA cuff systems. An earlier AU filing (2009, inactive) disclosed a method using cuff pressure oscillations during IPPV and spontaneous breathing to estimate anesthetic depth and trigger alarms when cuff pressure exceeds selected thresholds. The company’s filings span US, AU, and CA jurisdictions across 1993–2018, covering both foundational LMA drainage architecture and active cuff monitoring systems in retrieved records.
Canada / United StatesFive Emerging Technology Directions in LMA Cuff and Supraglottic Airway Innovation
The most recent filings and publications (2021–2025) in this dataset point to five converging directions: integrated visualization architectures, modular multi-cavity systems, self-sealing membrane cuffs, FEA-guided cuff design, and dedicated endoscopic LMA platforms.
Telescoping SGA with Integrated Camera (Covidien LP, 2024)
A 2024 US pending patent from Covidien LP describes a spring-biased telescoping airway channel designed to accommodate a camera at the distal end of the SGA cuff. This signals convergence of supraglottic sealing function with real-time endoscopic placement verification. The architecture potentially eliminates the need for separate fiberoptic confirmation of cuff position, reducing procedural steps in difficult airway management.
Baska Mask Self-Pressurizing Membrane Cuff
The Baska Mask employs a membrane cuff that adjusts seal pressure dynamically with airway pressure rather than relying on a fixed inflation volume. A 2023 RCT within this dataset demonstrated statistically significant superiority in seal pressure for Baska Mask versus ProSeal LMA, with shorter insertion time and lower leak fraction. This third-generation architecture represents an alternative to both inflatable cuff P-V curve optimization and non-inflatable gel cuffs.
Inflatable Cuff vs. Non-Inflatable Gel Cuff vs. Self-Pressurizing Membrane: Three LMA Sealing Paradigms
Click any row to explore further.
| Dimension | Inflatable Cuff (P-V Engineered) | Non-Inflatable Gel Cuff (i-gel) |
|---|---|---|
| Sealing Mechanism | Pneumatic inflation to target intracuff pressure; P-V curve engineered to prevent over-inflation | Thermoplastic elastomer gel that conforms anatomically at body temperature without inflation |
| Mean OLP Reported | 24–35 cmH₂O across second-generation devices in this dataset | Approximately 24–26 cmH₂O; comparable to inflatable LMA in clinical studies in this dataset |
| Cuff Pressure Management | Required; clinical target ≤25 cmH₂O; manufacturer maximum 60 cmH₂O | Not required; eliminates intracuff pressure monitoring entirely |
| Mucosal Injury Risk | Significant if pressure exceeds 25 cmH₂O; reduced with P-V curve self-regulation | Reduced by absence of inflation pressure; dependent on material conformity at body temperature |
| Prewarming Benefit | Not applicable — sealing is pressure-driven | 2022 meta-analysis confirms prewarming improves thermoplastic conformity and sealing performance |
| Key Active IP in Dataset | Airway Medix S.A. US patents (2019–2020) on P-V curve local maximum and plateau architecture | No direct patents in this dataset; extensively evaluated in clinical comparative literature |
| Self-Pressurizing Alternative | N/A for standard inflatable cuffs | Baska Mask (membrane cuff): dynamically adjusts seal with airway pressure; 2023 RCT shows higher OLP than ProSeal |
| Gastric Drainage | Available in second-generation devices (ProSeal, Supreme); foundational Teleflex 1993 patent establishes concentric drainage architecture | i-gel includes a drain tube channel; no inflation management required alongside drainage function |
Frequently Asked Questions: LMA Cuff Pressure Optimization
Based on clinical studies in this dataset, intracuff pressure should not exceed 60 cmH₂O (manufacturer maximum) and ideally should be limited to 25 cmH₂O to minimize postoperative pharyngolaryngeal adverse events. A 2014 prospective randomized study specifically demonstrated that limiting LMA Supreme cuff pressure to 25 cmH₂O reduced sore throat and dysphagia compared to inflation at 60 cmH₂O.
Across clinical studies in this dataset, mean OLPs for second-generation SGAs typically range from 24 to 35 cmH₂O. The Baska Mask demonstrated statistically higher seal pressure than ProSeal in a 2023 RCT, and LMA ProSeal and Supreme consistently reported OLPs in the 24–32 cmH₂O range across multiple trials.
Airway Medix S.A. (Israel) holds 3 active US patents (2019–2020) defining cuff geometries with a local pressure maximum between 15–120 cmH₂O at medium volumes and a sustained medium-pressure plateau at high volumes. The medium-pressure-range rate of change must be less than 0.5× the low-pressure-range rate. This self-regulating behavior prevents runaway over-inflation, and any entrant designing self-regulating inflatable LMA cuffs must design around these claims.
A 2010 study in this dataset found no statistically significant difference in leak pressure between i-gel and inflatable-cuff LMA, with i-gel eliminating cuff management entirely. A 2022 meta-analysis confirmed that prewarming non-inflatable cuff laryngeal masks improves thermoplastic conformity to laryngeal anatomy, enhancing seal. Mean OLPs for i-gel are approximately 24–26 cmH₂O in comparative studies within this dataset.
The Baska Mask employs a self-pressurizing membrane cuff that adjusts seal pressure dynamically with airway pressure rather than relying on a fixed inflation volume. In a 2023 RCT in this dataset, Baska Mask demonstrated statistically significant superiority in seal pressure versus ProSeal LMA, with shorter insertion time and lower leak fraction. This third-generation architecture differs from both inflatable P-V curve cuffs and non-inflatable gel cuffs.
Based on this dataset, key open opportunities include: combining self-regulating P-V curve cuffs with closed-loop pressure feedback (no granted patent has yet done this); developing endoscopic LMA platforms for GI procedures beyond the Zhejiang Jenston active US portfolio; and exploring self-pressurizing membrane cuff architectures in jurisdictions not yet covered by Baska Mask IP. Integrated visualization architectures (Covidien LP 2024 pending) and multi-cavity modular systems (Yang Ming EP 2025 pending) represent the most recent filed directions.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.